Cyclin D as a therapeutic target in cancer

By E. Musgrove, C. E. Caldon, J. Barraclough, Andrew Stone, Robert L. Sutherland. Nature Reviews. Cancer, 2011

1,362 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers (2013, background): “Cyclin D2 (CCND2) is deregulated in many human cancers, including MM (Bergsagel et al., 2005; Musgrove et al., 2011).”
MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer (2017, background): “CDK4 and CDK6, together with D-type cyclins, phosphorylate the Retinoblastoma (Rb) tumor-suppressor protein, leading to release of Rb-bound E2F, which enables progression from the G1 to S phase of the cell cycle (15, 16).”
Cyclin D1, Cancer Progression and Opportunities in Cancer Treatment (2016, background): “Clinicopathological studies showed that cyclin D1 overexpression correlates with tumor metastasis and poor prognosis in a series of human cancers [7, 123, 134].”
Discovery of multi-dimensional modules by integrative analysis of cancer genomic data (2012, background): “Mutations, amplification or overexpression of CCND1, which alter the cell cycle progression, are observed frequently in a variety of tumors (41,42).”
TARGETING CDK4 AND CDK6: FROM DISCOVERY TO THERAPY (2015, neutral): “Although several lines of evidence argue for CDK4/6-independent roles of D-type cyclins as transcriptional cofactors for HRs (68) and”